Bayer lands Airborne marketer Schiff in $1.2B buy

Share this article:

Bayer HealthCare inked a deal to acquire vitamin and supplement company Schiff Nutrition International, in a transaction valued at about $1.2 billion.

Schiff's product portfolio includes OTC brands MegaRed, Move Free and Airborne, among others.

“We will utilize our extensive marketing, sales and distribution expertise to further develop the strong brands we are acquiring,” said Dr. Jörg Reinhardt, CEO of Bayer HealthCare, the US subsidiary of Bayer AG.

The acquisition, announced Wednesday, brings to three the number of mid-size US companies the German pharma has bolted on in as many months. The others were crop protection firm AgraQuest, for $425 million in August, and Teva's US animal health business, for $145 million in September.

Bayer's move to bolster its US presence in the consumer health area follows that of some other big drugmakers. In 2009 Sanofi moved to acquire US-based consumer products firm Chattem for $1.9 billion, and this year Pfizer scooped up global rights to the OTC version of AstraZeneca GERD drug Nexium for $250 million up front and other milestone payments.

Then again, Pfizer sold its nutrition division to Nestle for $11.9 billion this year, as did Bristol-Myers Squibb in 2009, when it split off its Mead Johnson nutritional unit.

Some analysts have also called for Johnson & Johnson to divest its troubled McNeil consumer division, something new J&J CEO Alex Gorsky has resisted.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...